Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06060613 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Obsidian Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 9
- Study locations
NCT06060613 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Obsidian Therapeutics. The registered enrollment target is 52 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT06060613, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Obsidian Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL OBX-115
Study Locations (9)
California
- The Angeles Clinic and Research Institute (Melanoma) - Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC) - Los Angeles
- Stanford Cancer Institute (Melanoma/NSCLC) - Stanford
Florida
- Orlando Health Cancer Institute (Melanoma/NSCLC) - Orlando
Kentucky
- James Graham Brown Cancer Center (Melanoma/NSCLC) - Louisville
New York
- Memorial Sloan Kettering (Melanoma/NSCLC) - New York
Ohio
- The Ohio State University - Columbus
Pennsylvania
- Allegheny Research Institute (Melanoma/NSCLC) - Pittsburgh
Texas
- M.D. Anderson Cancer Center (Melanoma/NSCLC) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06060613
The ClinicalTrials.gov registry entry for NCT06060613 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Obsidian Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which OBX-115 is the first listed.
NCT06060613 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06060613 about?
NCT06060613 is a clinical study titled "Safety and Efficacy of OBX-115 in Advanced Solid Tumors". This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
What is the current status of trial NCT06060613?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2023-10-25. Estimated completion is 2028-06-30.
What conditions does trial NCT06060613 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Melanoma, Metastatic Melanoma, Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT06060613?
The interventions under investigation include: OBX-115 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06060613?
This trial is sponsored by Obsidian Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06060613 being conducted?
This trial has 9 study locations across California, Florida, Kentucky, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.